204 related articles for article (PubMed ID: 21411176)
41. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
42. Comprehensive CADM1 promoter methylation analysis in NSCLC and normal lung specimens.
van den Berg RM; Snijders PJ; Grünberg K; Kooi C; Spreeuwenberg MD; Meijer CJ; Postmus PE; Smit EF; Steenbergen RD
Lung Cancer; 2011 Jun; 72(3):316-21. PubMed ID: 21067843
[TBL] [Abstract][Full Text] [Related]
43. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
[TBL] [Abstract][Full Text] [Related]
44. Artificial neural networks and logistic regression as tools for prediction of survival in patients with Stages I and II non-small cell lung cancer.
Marchevsky AM; Patel S; Wiley KJ; Stephenson MA; Gondo M; Brown RW; Yi ES; Benedict WF; Anton RC; Cagle PT
Mod Pathol; 1998 Jul; 11(7):618-25. PubMed ID: 9688182
[TBL] [Abstract][Full Text] [Related]
45. Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer.
Suemitsu R; Yoshino I; Tomiyasu M; Fukuyama S; Okamoto T; Maehara Y
Surg Today; 2004; 34(11):896-901. PubMed ID: 15526122
[TBL] [Abstract][Full Text] [Related]
46. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
[TBL] [Abstract][Full Text] [Related]
47. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
48. Exploratory investigation of plasma metabolomics in human lung adenocarcinoma.
Wen T; Gao L; Wen Z; Wu C; Tan CS; Toh WZ; Ong CN
Mol Biosyst; 2013 Sep; 9(9):2370-8. PubMed ID: 23857124
[TBL] [Abstract][Full Text] [Related]
49. Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.
Hanas JS; Peyton MD; Lerner MR; Lightfoot SA; Deb SJ; Hanas RJ; Vu NT; Kupiec TC; Stowell DE; Brackett DJ; Dubinett SM; Hocker JR
Cancer Invest; 2014 May; 32(4):136-43. PubMed ID: 24579933
[TBL] [Abstract][Full Text] [Related]
50. Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease.
Deja S; Porebska I; Kowal A; Zabek A; Barg W; Pawelczyk K; Stanimirova I; Daszykowski M; Korzeniewska A; Jankowska R; Mlynarz P
J Pharm Biomed Anal; 2014 Nov; 100():369-380. PubMed ID: 25213261
[TBL] [Abstract][Full Text] [Related]
51. Probing gender-specific lipid metabolites and diagnostic biomarkers for lung cancer using Fourier transform ion cyclotron resonance mass spectrometry.
Guo Y; Wang X; Qiu L; Qin X; Liu H; Wang Y; Li F; Wang X; Chen G; Song G; Li F; Guo S; Li Z
Clin Chim Acta; 2012 Dec; 414():135-41. PubMed ID: 22906735
[TBL] [Abstract][Full Text] [Related]
52. In situ detection of lung cancer volatile fingerprints using bronchoscopic air-sampling.
Santonico M; Lucantoni G; Pennazza G; Capuano R; Galluccio G; Roscioni C; La Delfa G; Consoli D; Martinelli E; Paolesse R; Di Natale C; D'Amico A
Lung Cancer; 2012 Jul; 77(1):46-50. PubMed ID: 22264635
[TBL] [Abstract][Full Text] [Related]
53. Serum fatty acid profiling of colorectal cancer by gas chromatography/mass spectrometry.
Kondo Y; Nishiumi S; Shinohara M; Hatano N; Ikeda A; Yoshie T; Kobayashi T; Shiomi Y; Irino Y; Takenawa T; Azuma T; Yoshida M
Biomark Med; 2011 Aug; 5(4):451-60. PubMed ID: 21861667
[TBL] [Abstract][Full Text] [Related]
54. Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma.
Wikoff WR; Grapov D; Fahrmann JF; DeFelice B; Rom WN; Pass HI; Kim K; Nguyen U; Taylor SL; Gandara DR; Kelly K; Fiehn O; Miyamoto S
Cancer Prev Res (Phila); 2015 May; 8(5):410-8. PubMed ID: 25657018
[TBL] [Abstract][Full Text] [Related]
55. Metabolomic-based biomarker discovery for non-invasive lung cancer screening: A case study.
O'Shea K; Cameron SJ; Lewis KE; Lu C; Mur LA
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt B):2682-7. PubMed ID: 27423423
[TBL] [Abstract][Full Text] [Related]
56. Circulating MicroRNA Signatures of Tumor-Derived Exosomes for Early Diagnosis of Non-Small-Cell Lung Cancer.
Rosell R; Wei J; Taron M
Clin Lung Cancer; 2009 Jan; 10(1):8-9. PubMed ID: 19289365
[No Abstract] [Full Text] [Related]
57. Detection and verification of coexisting diagnostic markers in plasma and serum of patients with non-small-cell lung cancer.
Yu M; Sun R; Zhao Y; Shao F; Zhu W; Aa J
Future Oncol; 2021 Nov; 17(32):4355-4369. PubMed ID: 34674559
[TBL] [Abstract][Full Text] [Related]
58. Serum and tissue metabolomics of head and neck cancer.
Yonezawa K; Nishiumi S; Kitamoto-Matsuda J; Fujita T; Morimoto K; Yamashita D; Saito M; Otsuki N; Irino Y; Shinohara M; Yoshida M; Nibu K
Cancer Genomics Proteomics; 2013; 10(5):233-8. PubMed ID: 24136976
[TBL] [Abstract][Full Text] [Related]
59. Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice.
Jett JR; Peek LJ; Fredericks L; Jewell W; Pingleton WW; Robertson JF
Lung Cancer; 2014 Jan; 83(1):51-5. PubMed ID: 24268382
[TBL] [Abstract][Full Text] [Related]
60. Metabolomic profiling of human serum in lung cancer patients using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry and gas chromatography/mass spectrometry.
Chen Y; Ma Z; Li A; Li H; Wang B; Zhong J; Min L; Dai L
J Cancer Res Clin Oncol; 2015 Apr; 141(4):705-18. PubMed ID: 25293627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
